ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cost-Effectiveness of Percutaneous Coronary Intervention with Drug-Eluting Stents vs. Bypass Surgery for Patients with 3-Vessel or Left Main Coronary Artery Disease: Final Results from the SYNTAX Trial.

Friday, August 8, 2014

Submitted by

Ruben Osnabrugge

Source

Source Name: Circulation

Source URL: http://www.ncbi.nlm.nih.gov/pubmed/25085960

Author(s)

Cohen DJ, Osnabrugge RL, Magnuson EA, Wang K, Li H, Chinnakondepalli K, Pinto D, Abdallah MS, Vilain KA, Morice MC, Dawkins KD, Kappetein AP, Mohr FW, Serruys PW.

In this study the cost-effectiveness of CABG vs. DES-PCI was analysed from a U.S. Healthcare perspective. Using 5-year cost and quality-of-life data from the SYNTAX trial and lifetime extrapolations, the authors found that CABG was an economically attractive treatment option for most patients with 3-VD or left main CAD disease.